CN116199782A - 预防和/或治疗血栓栓塞性疾病的方法 - Google Patents

预防和/或治疗血栓栓塞性疾病的方法 Download PDF

Info

Publication number
CN116199782A
CN116199782A CN202211512928.9A CN202211512928A CN116199782A CN 116199782 A CN116199782 A CN 116199782A CN 202211512928 A CN202211512928 A CN 202211512928A CN 116199782 A CN116199782 A CN 116199782A
Authority
CN
China
Prior art keywords
seq
fxi
single variable
variable domain
immunoglobulin single
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202211512928.9A
Other languages
English (en)
Chinese (zh)
Inventor
徐霆
尹群
鄢荣梅
李倩
王燕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Alphamab Co Ltd
Original Assignee
Suzhou Alphamab Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Alphamab Co Ltd filed Critical Suzhou Alphamab Co Ltd
Publication of CN116199782A publication Critical patent/CN116199782A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202211512928.9A 2021-11-30 2022-11-29 预防和/或治疗血栓栓塞性疾病的方法 Pending CN116199782A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111439560 2021-11-30
CN2021114395603 2021-11-30

Publications (1)

Publication Number Publication Date
CN116199782A true CN116199782A (zh) 2023-06-02

Family

ID=86516220

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202211512928.9A Pending CN116199782A (zh) 2021-11-30 2022-11-29 预防和/或治疗血栓栓塞性疾病的方法

Country Status (5)

Country Link
US (1) US20250034277A1 (https=)
EP (1) EP4442273A4 (https=)
JP (1) JP2024544057A (https=)
CN (1) CN116199782A (https=)
WO (1) WO2023098637A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025237307A1 (zh) * 2024-05-14 2025-11-20 苏州康宁杰瑞生物科技有限公司 凝血因子FXI/FXIa抑制剂用于治疗肺动脉高压和/或高血压
WO2026032397A1 (en) * 2024-08-09 2026-02-12 Zai Lab (Shanghai) Co., Ltd. Binding molecules with an interleukin-31 receptor subunit alpha-antigen-binding domain and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
CN102558355B (zh) 2011-12-31 2015-02-25 苏州康宁杰瑞生物科技有限公司 基于电荷网络的异二聚体fc改造方法及异二聚体蛋白的制备方法
CN102851338A (zh) 2012-07-25 2013-01-02 苏州康宁杰瑞生物科技有限公司 利用电荷排斥作用制备同二聚体蛋白混合物的方法
RU2757314C2 (ru) * 2016-01-22 2021-10-13 Мерк Шарп И Доум Корп. Антитела против фактора свертывания xi
IL315266A (en) * 2016-06-14 2024-10-01 Merck Sharp ַ& Dohme Llc Anti-coagulation factor xi antibodies
CN113880949A (zh) * 2020-07-03 2022-01-04 苏州康宁杰瑞生物科技有限公司 凝血因子xi(fxi)结合蛋白
CA3188566A1 (en) * 2020-07-03 2022-01-06 Suzhou Alphamab Co., Ltd. Coagulation factor xi (fxi) binding protein
CN113880951A (zh) * 2020-07-03 2022-01-04 苏州康宁杰瑞生物科技有限公司 凝血因子xi(fxi)结合蛋白
CN113880950A (zh) * 2020-07-03 2022-01-04 苏州康宁杰瑞生物科技有限公司 凝血因子xi(fxi)结合蛋白

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025237307A1 (zh) * 2024-05-14 2025-11-20 苏州康宁杰瑞生物科技有限公司 凝血因子FXI/FXIa抑制剂用于治疗肺动脉高压和/或高血压
WO2026032397A1 (en) * 2024-08-09 2026-02-12 Zai Lab (Shanghai) Co., Ltd. Binding molecules with an interleukin-31 receptor subunit alpha-antigen-binding domain and uses thereof

Also Published As

Publication number Publication date
WO2023098637A1 (zh) 2023-06-08
JP2024544057A (ja) 2024-11-27
US20250034277A1 (en) 2025-01-30
EP4442273A4 (en) 2025-12-24
EP4442273A1 (en) 2024-10-09

Similar Documents

Publication Publication Date Title
JP6505288B2 (ja) 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法
IL240898A (en) Anti-c5a antibodies for manufacture of medicaments for treating complement-associated disorders
US20150010536A1 (en) Humanized PAI-1 Antibodies and Uses Thereof
US20240067720A1 (en) Anti-tigit antibody pharmaceutical composition and application thereof
CN116199782A (zh) 预防和/或治疗血栓栓塞性疾病的方法
TW202214701A (zh) 抗ＦＸＩ／ＦＸＩａ抗體、其抗原結合片段及醫藥用途
US20240294669A1 (en) Dosing regimens of factor xi/xia antibodies
EP4624493A1 (en) Pharmaceutical composition comprising bispecific antibody specifically binding to hgfr and egfr
JP6002354B1 (ja) Ａｎｇ２抗体
EP4076511A1 (en) Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies
KR101581517B1 (ko) Tgf-알파 및 에피레굴린에 결합하는 항체
CN115803348B (zh) 凝血因子xi(fxi)结合蛋白
KR20250037482A (ko) 항-인자 xi/인자 xia 항체와의 조합 요법
CN120695174A (zh) 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用
CN107043423B (zh) 凝血酶抗体、其抗原结合片段及医药用途
EP4729541A1 (en) Anti- igfbp7 antibodies and uses thereof
WO2026092502A1 (zh) 一种包含抗tf抗体药物偶联物的药物组合物
HK40084746A (en) Coagulation factor xi (fxi) binding protein
AU2024292030A1 (en) Targeted treatment of complement-mediated disease through local complement inhibition based on urinary uc5b-9 detection
CN115531531A (zh) 抗人vegf抗体和化疗联用在制备治疗结直肠癌药物中的用途
CN120437287A (zh) 一种包含特异性结合gucy2c和cd3的双特异性抗体的药物组合物
KR20260052059A (ko) 소변 uC5b-9 검출에 기반한 국소 보체 억제를 통한 보체-매개 질환의 표적 치료
CN119909167A (zh) 一种包含抗ccr8抗体的药物组合物及其用途
HK1190410B (en) Antibodies that bind tgf-alpha and epiregulin

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination